Oral Mucosa in Cancer Patients-Putting the Pieces Together: A Narrative Review and New Perspectives
- PMID: 37444405
- PMCID: PMC10340546
- DOI: 10.3390/cancers15133295
Oral Mucosa in Cancer Patients-Putting the Pieces Together: A Narrative Review and New Perspectives
Abstract
The oral mucosa is a key player in cancer patients and during cancer treatment. The increasing prevalence of cancer and cancer-therapy-associated side effects are behind the major role that oral mucosa plays in oncological patients. Oral mucositis is a debilitating severe complication caused by the early toxicity of chemo and/or radiotherapy that can restrict treatment outcome possibilities, even challenging a patient's survival. It has been referred to as the most feared cancer treatment complication. Predictive variables as to who will be affected, and to what extent, are still unclear. Additionally, oral mucositis is one of the sources of the increasing economic burden of cancer, not only for patients and their families but also for institutions and governments. All efforts should be implemented in the search for new approaches to minimize the apparently ineluctable outburst of oral mucositis during cancer treatment. New perspectives derived from different approaches to explaining the interrelation between oral mucositis and the oral microbiome or the similarities with genitourinary mucosa may help elucidate the biomolecular pathways and mechanisms behind oral mucosa cancer-therapy-related toxicity, and what is more important is its management in order to minimize treatment side effects and provide enhanced cancer support.
Keywords: antioxidant; breast cancer survivors; cancer support; cancer toxicity; head and neck cancer; microbiome boost; mucositis; oral mucosa; saliactive; vagina.
Conflict of interest statement
Debora R. Vilaboa and Beatriz R. Vilaboa are founding members of the company Mucosa Innovations S.L. Mucosa Innovations is the owner and developer of technology specifically focused on mucosal cancer-therapy-related toxicities, microbiome modulation pathways, and mucosa-related women’s health conditions. No known conflict of interest exists for the rest of the authors.
References
-
- Celebi Sozener Z., Ozturk B.O., Cerci P., Turk M., Akin B.G., Akdis M., Altiner S., Ozbey U., Ogulur I., Mitamura Y., et al. Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease. Allergy. 2022;77:1418–1449. doi: 10.1111/all.15240. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources